报告期内，公司未发生用闲置募集资金暂时补充流动资金情况。 成都苑东生物制药股份有限公司 专项报告 成都苑东生物制药股份有限公司（以下简称"苑东生物"、"本公司"或"公司"） 董事会根据《上海证券交易所科创板上市公司自律监管规则适用指引第 1 号——规 范运作》及相关格式指引的要求，编制了《2025 年半年度募集资金存放、管理与 实际使用情况的专项报告》。具体如下： 一、募集资金基本情况 （一） 实际募集资金金额、资金到账时间 公司经中国证券监督管理委员会"证监许可[2020]1584 号"《关于同意成都苑东 生物制药股份有限公司首次公开发行股票注册的批复》同意注册，向社会公开发行 了人民币普通股（A 股）股票 3,009.00 万股，发行价为每股人民币 44.36 元，共计 募集资金总额为人民币 1,334,792,400.00 元，扣除发行费用（不含税）人民币 况业经中汇会计师事务所（特殊普通合伙）审验，并由其于 2020 年 8 月 26 日出具 了《验资报告》（中汇会验[2020] 5681 号）1。 （二） 募集金额使用情况和结余情况 截至 2025 年 6 月 30 日，结余募集资金（含利息收入扣除 ...

Core Viewpoint - Enhua Pharmaceutical reported continuous growth in its operating performance for the first half of 2025, with revenue reaching 3.01 billion yuan, an increase of 8.93% year-on-year, and a net profit attributable to shareholders of 700 million yuan, up 11.38% year-on-year [1] Financial Performance - The company achieved an operating revenue of 3.01 billion yuan, reflecting an 8.93% increase compared to the same period last year [1] - The net profit attributable to shareholders was 700 million yuan, marking an 11.38% year-on-year growth [1] - The net profit after deducting non-recurring gains and losses was 699 million yuan, which is a 10.33% increase year-on-year [1] R&D Investment - Enhua Pharmaceutical invested approximately 395 million yuan in research and development, representing a 23.97% increase compared to the previous year [2] - The company has over 70 ongoing research projects in the pipeline and holds the largest product line in the central nervous system drug sector in China [2] Innovative Drug Development - The company has 17 innovative drug projects under development, including 1 project in Phase III clinical trials and 2 projects in Phase II clinical trials [3] - Collaborations include partnerships with San Sheng Pharmaceutical and Harvard Medical School for various drug development projects [3] Digital Healthcare Development - Enhua Pharmaceutical has established a digital healthcare platform since 2015, which includes online consultation and health services, with over 70,000 registered doctors and more than 2 million patient visits annually [4] - The company has developed several digital mental health products, including AI-based psychological risk screening systems and virtual reality tools [4] Expansion and Partnerships - The company operates 25 psychological clinics and has signed contracts with over 400 corporate clients, covering nearly 2 million individuals [5] - Enhua Pharmaceutical is actively pursuing overseas listing plans to expand financing channels and support business growth [5]

Summary of Key Points Core Viewpoint The report outlines the process and results of a share transfer inquiry by Chengdu Yuandong Pharmaceutical Co., Ltd. to specific institutional investors, facilitated by CITIC Securities, ensuring compliance with relevant regulations and fairness in the transfer process [1][5][12]. Group 1: Overview of the Share Transfer - The share transfer involves three entities: Chengdu Nanyuan Investment Partnership, Chengdu Zhuyuan Investment Partnership, and Chengdu Juyuan Investment Partnership, collectively referred to as the "transferors" [1]. - The maximum number of shares proposed for transfer is 3,369,550 shares, representing 1.91% of the total share capital of the company [6][8]. - The transferors hold pre-IPO shares, with specific quantities and ownership percentages detailed for each entity [1][6]. Group 2: Pricing and Transfer Process - The minimum price for the share transfer was determined based on the transferors' financial needs and is not lower than the price set in the subscription invitation sent by CITIC Securities [2]. - The transfer price was finalized at 42.06 yuan per share, resulting in a total transaction amount of 141,723,273 yuan [6][8]. - The transfer process involved sending subscription invitations to 418 institutional investors, including various types of investment firms [5][6]. Group 3: Compliance and Verification - CITIC Securities conducted thorough checks on the qualifications of both the transferors and the transferees, ensuring compliance with the relevant regulations [10][11]. - The report confirms that all participating institutional investors met the necessary criteria and did not have any conflicts of interest with the transferors [12]. - The entire share transfer process adhered to the principles of fairness and compliance with applicable laws and regulations [12][13].

Core Viewpoint - The nomination of Li Weifeng as an independent director candidate for Chengdu Yuandong Pharmaceutical Co., Ltd. has been made by the controlling shareholder Wang Ying, who asserts that the candidate meets all necessary qualifications and independence criteria [1][5]. Summary by Relevant Sections Nomination and Qualifications - Wang Ying, the controlling shareholder, has nominated Li Weifeng as an independent director candidate for the fourth board of Chengdu Yuandong Pharmaceutical Co., Ltd. The nominee has agreed to the position and possesses the required professional knowledge and experience [1]. - The nominee has over 5 years of relevant work experience in law, economics, accounting, finance, or management, and has completed the necessary training for independent directors [1]. Compliance with Regulations - The nominee's qualifications comply with various legal and regulatory requirements, including the Company Law of the People's Republic of China and the regulations set forth by the China Securities Regulatory Commission [1]. - Specific regulations regarding the independence of directors have been adhered to, ensuring that the nominee does not fall under any disqualifying conditions [2][3]. Independence Criteria - The nominee is confirmed to be independent, not holding any significant shares or positions that could compromise their impartiality [2][3]. - The nominee has no adverse records, such as administrative or criminal penalties from the China Securities Regulatory Commission in the last 36 months [4]. Additional Information - The nominee has not served as an independent director in more than three domestic listed companies and has not held the position in Chengdu Yuandong Pharmaceutical Co., Ltd. for more than six years [4]. - The nomination has passed the qualification review by the board's nomination committee, confirming no conflicts of interest exist between the nominator and the nominee [4].

深圳价值在线咨询顾问有限公司 关于 成都苑东生物制药股份有限公司 首次授予部分第一个归属期符合归属条件 相关事项 之 独立财务顾问报告 二〇二五年六月 深圳价值在线咨询顾问有限公 司 独立财务顾问报告 目 录 深圳价值在线咨询顾问有限公司 独立财务顾问报告 第一章 释 义 在本报告中，如无特殊说明，下列简称具有如下含义： 释义项 释义内容 苑东生物、本公司、公司 指 成都苑东生物制药股份有限公司 限制性股票激励计划、本次激 成都苑东生物制药股份有限公司 2024 年限制性股票 指 励计划 激励计划 《成都苑东生物制药股份有限公司 2024 年限制性股 《激励计划（草案）》 指 票激励计划（草案）》 《深圳价值在线咨询顾问有限公司关于成都苑东生 物制药股份有限公司 2024 年限制性股票激励计划首 本报告、本独立财务顾问报告 指 次授予部分第一个归属期符合归属条件相关事项之 独立财务顾问报告》 独立财务顾问、价值在线 指 深圳价值在线咨询顾问有限公司 限制性股票、第二类限制性股 符合本次激励计划授予条件的激励对象，在满足相应 指 票 归属条件后分次获得并登记的本公司股票 按照本次激励计划规定，获得限制性股票的公 ...

北京植德律师事务所 关于成都苑东生物制药股份有限公司 法律意见书 植德京(会)字20250061 号 二〇二五年五月 北京市东城区东直门南大街 1 号来福士中心办公楼 12 层 邮编：100007 Dongcheng District, Beijing 100007 P.R.C 电话(Tel)：010-56500900 传真(Fax)：010-56500999 北京植德律师事务所 关于成都苑东生物制药股份有限公司 法律意见书 植德京(会)字20250061 号 www.meritsandtree.com 致：成都苑东生物制药股份有限公司（贵公司） 北京植德律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出 席并见证贵公司 2024 年年度股东大会（以下简称"本次会议"）。 本所律师参加本次会议进行见证，并根据《中华人民共和国公司法》（以下 简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司股东会规则》（以下简称"《股东会规则》"）、《律师事务所从事 证券法律业务管理办法》（以下简称"《证券法律业务管理办法》"）、《律师 事务所证券法律业务执业规则（试行）》 （以下简 ...

Core Viewpoint - The announcement highlights that Zhuzhou Qianjin Pharmaceutical Co., Ltd.'s subsidiary, Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd., has received drug registration certificates for Fumarate Bisoprolol Tablets (2.5mg, 5mg) from the National Medical Products Administration, indicating successful compliance with drug registration requirements [1][2]. Group 1: Drug Information - Drug Name: Fumarate Bisoprolol Tablets - Dosage Forms: Tablets - Specifications: 2.5mg, 5mg - Registration Classification: Class 4 Chemical Drug - Approval Numbers: National Drug Approval Code H20253939, H20253940 - License Holder: Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. [1][2]. Group 2: Market Context - Fumarate Bisoprolol Tablets are selective β-receptor blockers used for treating hypertension, coronary heart disease (angina), and chronic stable heart failure with reduced left ventricular function (ejection fraction ≤ 35%). - The drug was first launched in Germany in 1986 and entered the Chinese market in 1998. Other manufacturers with registration include Merck Germany and Chengdu Yuandong Biological Pharmaceutical Co., Ltd. - The domestic market sales for Fumarate Bisoprolol Tablets in 2023 are approximately RMB 1.342 billion [2]. Group 3: Company Impact - The receipt of the drug registration certificate for Fumarate Bisoprolol Tablets signifies passing the consistency evaluation, enhancing the company's product pipeline and supporting sustainable development. - The company has invested a total of RMB 7.1965 million in the research and development of Fumarate Bisoprolol Tablets (2.5mg, 5mg) [2][3].

Core Viewpoint - The resignation of core technical personnel, Mr. Zhu Hua, will not adversely affect the company's operational capabilities, research and development strength, or core competitiveness [1][7]. Group 1: Resignation Details - Mr. Zhu Hua resigned for personal career development reasons and will no longer hold any position within the company [1]. - Mr. Zhu Hua has been with the company since 2020, serving in various roles including Technical Director and Chief Engineer, and was recognized as a core technical personnel in July 2022 [1]. - There are no disputes or potential disputes regarding job results or intellectual property related to Mr. Zhu's departure, ensuring the integrity of the company's patents and intellectual property [1][3]. Group 2: Impact on the Company - The company has a rich reserve of research personnel, with 428 R&D staff members as of June 2024, accounting for 28.90% of the total workforce, including 173 with master's or doctoral degrees [4]. - The company has established a mature and comprehensive R&D system, with six drug research institutes in various locations, ensuring that R&D activities do not heavily rely on individual personnel [6]. - The company's production and R&D activities are currently operating normally, with Mr. Zhu's work having been successfully handed over [6][8]. Group 3: Measures Taken by the Company - The company has a complete technical R&D team structure and a robust management system, with sufficient backup personnel to support ongoing core technology development and innovation [8]. - A comprehensive talent cultivation system is in place, allowing for dual career paths in technical and management roles, ensuring a steady supply of talent for R&D innovation [8].